A one-year observation of the effect of oral risperidone on schizophrenia patients switching to PP1M
Objective Evaluate the treatment effect of oral risperidone switching to once-monthly paliperidone palmitate(PP1M)for a 1-year period in patients with schizophrenia.Methods Eighty patients with schizophrenia who responded well to oral risperidone were randomly divided into two groups(injection group and oral drug group),with 40 cases in each group.At baseline and after 12 months of treatment,PANSS,PSP,and BEMIB were used to assess the patients in both groups,and relevant adverse drug reactions were collected.Results There were no significant differ-ences in the total PANSS scores and subscale scores between the two groups before and after treatment(P＞0.05).After treatment,the PANSS total scores and subscale scores within the group were significantly lower than before treatment,with statistical significance(P＜0.05).There were no significant differences in the PSP scores between the two groups at baseline(P＞0.05).After treatment,the PSP scores of both groups increased.In terms of"beneficial activities for society","disruption and aggressive behavior",and the total PSP score,the study group scores were significantly higher than the control group,with statistical significance(P＜0.05).There were no signifiicant differences in the BE-MIB scores between the two groups at baseline(P＞0.05).After treatment,the BEMIB score of the study group was significantly higher than that of the control group,with statistical significance(P＜0.05).The incidence of adverse drug reactions in the two groups was 52.6％and 40.0％,respectively,with no significant differences(P＞0.05).Conclusions In the treatment of schizophrenia,PP1M can be used as an alternative to oral risperidone,effectively controlling patients'clinical symptoms,better improving their social function and medication adherence,and having drug adverse reactions that are similar to those of oral drugs.It is worth promoting in clinical practice.
NETL
NSTL
万方数据
